NCT06649331 2026-03-17
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Fudan University
Phase 2 Recruiting
Clinical Trials
18 trialsNCT07382713 2026-02-03
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07355010 2026-01-21
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT07143292 2025-11-18
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06516289 2024-12-12
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Fudan University
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT06336954 2024-03-29
Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 2 Not yet recruiting
NCT06332950 2024-03-27
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting
NCT05999149 2024-02-21
BCTOP-T-N01
Fudan University
Phase 3 Recruiting
NCT04395989 2023-12-22
FUTURE-SUPER
Fudan University
Phase 2 Unknown
NCT06146985 2023-11-28
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Ruijin Hospital
Phase 2 Unknown
NCT04733417 2023-04-13
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05051865 2022-11-17
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT04129996 2022-01-11
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
Phase 2 Unknown
NCT04866381 2021-04-29
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04044378 2020-05-19
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Peking University People's Hospital
Phase 1/2 Withdrawn